RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy
Lin Mao1, Yangjing Ou1, Yuchao Zhang1
1Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Cancer Immunology, Immunotherapy : CII
|March 17, 2026
Summary
Removing RIPK1 in dendritic cells (DCs) enhances anti-tumor immunity. This DC-specific Ripk1 knockout boosts T cell interactions and inhibits tumor growth, offering a new strategy for DC-based cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Dendritic Cell (DC)-based vaccines are promising tumor immunotherapies, but their efficacy needs improvement.
- RIPK1, a regulator of inflammation and cell death, may influence DC anti-tumor functions.
Purpose of the Study:
- To investigate the role of RIPK1 in DC-mediated anti-tumor immunity.
- To evaluate the potential of DC-specific RIPK1 knockout as a strategy to enhance DC vaccine efficacy.
Main Methods:
- Generated mice with DC-specific knockout of the Ripk1 gene.
- Assessed tumor growth, immune cell infiltration, and cytotoxic T cell interactions in the tumor microenvironment.
- Performed in vitro experiments to analyze DC antigen presentation and T cell activation.
- Vaccinated tumor-bearing mice with RIPK1-knockout DCs and compared efficacy against wild-type DCs.
Main Results:
- DC-specific Ripk1 knockout inhibited tumor growth in mice.
- Knockout enhanced DC immune infiltration and cytotoxic T cell interactions within the tumor microenvironment.
- In vitro studies showed augmented antigen presentation and activation of DCs and CD8+ T cells.
- Vaccination with RIPK1-knockout DCs effectively suppressed tumor growth compared to wild-type DCs.
Conclusions:
- DC-specific RIPK1 knockout enhances anti-tumor immunity by improving DC function and T cell activation.
- RIPK1 represents a potential novel target for optimizing DC-based cancer vaccines.
